IL-4/IL-13 Inhibitors: Dupilumab vs IL-13-Selective Agents

Dupixent now spans nine indications while Adbry and Ebglyss block IL-13 alone in atopic dermatitis. A clinician guide to indications, safety, interactions, and monitoring.
Medscape Medical News